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Sonic hedgehog pathwayEsophageal atresia is a common and life-threatening birth defectwith a poorly understood etiology. In this study,
we analyzed the sequence variants of coding regions for a set of esophageal atresia-related genes including
MYCN, SOX2, CHD7, GLI3, FGFR2 and PTEN for mutations using PCR-based target enrichment and next-
generation sequencing in 27 patients with esophageal atresia. Genomic copy number variation analysis was
performed using Affymetrix SNP 6.0. We found a de novo heterozygous mutation in the N-terminal region of
the GLI3 gene (c.332 T N C, p.M111T) in a patient with esophageal atresia and hemivertebrae. The N-terminal
region (amino acids 1–397) of GLI3 contains the repressor domain, which interacts with SKI family proteins.
Using the co-immunoprecipitation assay, we found that interaction of GLI3 with the SKI family protein SKIL
was signiﬁcantly compromised by the p.M111T mutation of GLI3. Thus far, all the identiﬁed mutations mapped
within the repressor domain ofGLI3were nonsense and frame-shiftmutations. In this study, amissensemutation
was initially detected in this region. Our ﬁnding is theﬁrst to link thisGLI3 genemutationwith esophageal atresia
in humans, which was previously suggested in an animal model.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Esophageal atresia (EA) is a developmental defect of the upper
gastrointestinal tract in which the continuity between the upper
and lower esophagus is lost. Esophageal atresia with or without
tracheo-esophageal ﬁstula (TEF) is a rare malformation, occurring
in approximately 1 in 3500 births [1]. Although the underlying mo-
lecular mechanism remains obscure in most patients with EA/TEF,
it has been associated with a wide spectrum of genetic syndromes
caused by genetic alterations including mutations in single genes
or chromosome aberrations [2].
Approximately 6% to 10% of syndromic EA/TEF is associated with
chromosomal anomalies [3]. The majority is represented by trisomies
(trisomy 13, 18, 21) [2,4] or microdeletions of 22q11 [5], 17q22–, Children's Hospital of Fudan
Tel./fax: +86 21 64931003.17q23.3 [6] and 16q24.1 [7]. Meanwhile, mutations ofMYCN, SOX2 and
CDH7 have also been reported to be responsible for syndromic EA, such
as Feingold syndrome, AEG syndrome (Anophthalmia-esophageal–
genital syndrome) and CHARGE association (coloboma, heart anomaly,
choanal atresia, retardation, and genital and ear anomalies) [8]. Deletions
and mutations in the GLI3 and FGFR2 genes are responsible for Pallister–
Hall syndrome and Apert syndrome, respectively, in which EA is infre-
quently reported [9–11]. In rare cases, mutations in PTEN have been
reported in the VATER association (vertebral defects, anal atresia,
tracheoesophageal ﬁstula with esophageal atresia, and radial or renal
dysplasia) [12].
In this study, we searched for sequence variants in the protein-
coding regions of the humanMYCN, SOX2, CHD7, GLI3, FGFR2 and PTEN
genes by PCR-based target enrichment followed by next-generation se-
quencing using the Ion Torrent Personal Genome Machine™ (PGMTM,
Life Technologies, Carlsbad, CA). We also analyzed genomic copy
number variants (CNVs) in 27 patients with EA/TEF. We found a de
novo heterozygous mutation in the N-terminal region of the GLI3 gene
(c.332 T N C, p.M111T). Our ﬁnding is the ﬁrst to link the GLI3 gene
mutation with esophageal atresia in humans, which was previously
suggested in an animal model.
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2.1. Subjects and DNA extraction
The subjects included 27 neonates with either isolated (6 neonates,
22.2%) or syndromic (21 neonates, 77.8%) forms of EA/TEF (Table 1).
Among these neonates, 14 (52%) were female and 13 (48%) were
male. Routine chromosome analysis was normal. The samples used in
this study were collected with appropriate informed consent and the
approval of the ethics committees of Children's Hospital, Fudan
University.
Genomic DNA was extracted from whole blood using the QIAamp
DNA Blood Mini kit (Qiagen, Hilden, Germany). DNA concentration
was measured using a Nano-Drop spectrophotometer (ND-1000,
Thermo Fisher Scientiﬁc, Waltham, MA).
2.2. Candidate genes sequencing
Analysis of the protein-coding regions of the human MYCN, SOX2,
CHD7, GLI3, FGFR2 and PTEN genes were performed using Ion Torrent
PGMTM. The complete target genes have 43 amplicons (from 652 bp to
7936 bp) covering all exons and at least 20 bp of all intron/splice sites.
The library was prepared by following the instructions provided by
the manufacturers of kits for fragmentation (Ion Shear, Life Technolo-
gies), adaptor and barcode ligation (Ion Xpress Barcode Adapters Kit,
Life Technologies) and library quantiﬁcation (Ion Library Quantiﬁcation
Kit, Life Technologies). We used the Ion OneTouch™ system (Life Tech-
nologies) to clonally amplify pooled barcoded libraries on Ion Sphere™
particles. Torrent Suite™ software was used to compare base calls.
NextGENeTM software was used to read alignments and to call variant
with the human genomic reference hg19 (NCBI). The variants selected
for further analysis met the following criteria: 1) The variant wasTable 1
Summary of clinical features of all included patients. Note: PDA: patent ductus arteriosus, P
hypertension, ASD: atrial septal defect, PLSVC: persistent left superior vena cava, TAPVD: total
Patient
ID
Gender Isolated/non-isolated Gastrointestinal Skeletal Heart
29 M Non-isolated – Polydactyly
30 M Non-isolated – – VSD, PDA,
107 M Isolated – –
208 M Non-isolated – – VSD, PDA,
296 F Non-isolated – – CHD
309 F Non-isolated – Polydactyly –
328 F Isolated – – –
329 M Non-isolated – Hemivertebrae –
332 F Non-isolated – – ASD, PDA
343 F Non-isolated Anal atresia,
anorectal ﬁstula
Polydactyly –





386 F Isolated – – –
396 F Non-isolated Anorectal ﬁstula – ASD, PPHN
PLSVC
399 F Isolated – – –
405 M Non-isolated Meckel's
diverticulum
– VSD, PDA,
w24 M Non-isolated – – VSD, ASD,
w43 M Non-isolated – – VSD, PDA,
w44 M Non-isolated – – PDA, PFO,
w46 F Non-isolated – Polydactyly –
611 M Non-isolated – – PDA, PFO
612 F Non-isolated – – TAPVD, DO
pulmonar
613 F Non-isolated – Hemivertebrae –
614 M Non-isolated – – VSD, PDA,
615 M Non-isolated Anal atresia – PDA, ASD
617 M Isolated – – –
618 F Isolated – – –
619 M Non-isolated – – PDA, ASDdetected in sequence reads for both strands, 2) a minimum coverage
of 10× was achieved, 3) the variant reads represented N20% of the
sequence reads at a particular site, 4) the targeted region covered all
exons and at least 20 bp of all intron/splice sites. The ﬁltered variants
were then compared with dbSNP (http://www.ncbi.nlm.nih.gov/
projects/SNP/). Novel Variants of unknown signiﬁcance (VUS) were an-
alyzed with in silico tools SIFT (http://sift.jcvi.org/) and PolyPhen2
(http://genetics.bwh.harvard.edu/pph2/).
2.3. Validation by Sanger sequencing
The variants were validated by PCR followed by direct Sanger
sequencing using an automated sequencer (3500XL Genetic Analyzer,
Applied Biosystems, Foster City, CA).
2.4. In vitro binding assay and co-immunoprecipitation
The human N-terminal GLI3 (397 amino acids) gene was obtained
from GenScript (Piscataway, NJ). The hGli3N sequence was inserted
into pRK5 with an HA tag to produce the WT hGli3N plasmid. The
hGli3N mutation was generated based on this construct. In brief,
Gli3N-M111T was generated using KOD-Plus (Toyobo, Osaka, Japan)
according to the manufacturer's instructions. Primers used in the point
mutation assay were For 5′-acggaccccaggaatggttacatgg-3′ and Rev 5′-
ggcaaacaccgtcccgcggtacggc-3′. Antibodies used in this study were
against the HA epitope tag (#M20013, Abmart) and SKIL (#19218-1-
AP, Proteintech). The plasmid expressing either HA-tagged wild-type
or p.M111T-mutant N-terminal GLI3 (397 amino acids) was transfected
into 293 T cells.
For co-IP of 293 T cells, HEK293T cells were plated on 6-well plates,
and transfectionwas performedwhen the cells reached 50% conﬂuence.
Lipofectamine2000 (Invitrogen, Carlsbad, CA)was used for transfection.FO: patent foramen ovale, VSD: ventricular septal defect, PPHN: persistent pulmonary
anomalous pulmonary venous drainage, DORV: double outlet of right ventricle.
Urogenital Dysmorphic Additional anomalies
Hypospadia –
PFO Hypospadia – –
PPHN – – –






PPHN – – –
– – –
, aortic coarctation, – – –
– – –
PFO – –
PDA, PPHN – – Diabetes mellitus
PFO – – –
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Cells were harvested 48 h after transfection. The cells were harvested
and lysed for 10 min at 4 °C in RIPA buffer. A total of 25% of the super-
natant was saved for the input control, and the rest was incubated
with 2 μg anti-HA agarose beads (Abmart, Beijing, China) overnight at
4 °C. The immune complex was washed three times with the lysis buff-
er, then boiled in 1× SDS loading buffer with 20 mM DTT and resolved
by 8% SDS-PAGE. The gel was transferred onto a PVDF membrane
(Amersham Pharmacia Biotech, Uppsala, Sweden), and the membrane
was blocked with 5% milk in TBST buffer for 1 h. The membrane was
then incubated overnight at 4 °C with 1:1000 anti-SKIL antibodies,
washed three times in TBST, then incubated for 2 h at room temperature
with 1:3000 secondary antibodies, and after three timeswashing in TBST,
the signalswere revealed byHRP reaction using the Supersignal chemilu-
minescent substrate (Pierce, Rockford, IL). The co-immunoprecipitated
endogenous SKIL was normalized to the HA-tagged hGli3N. The data
were analyzed with Students' T-test with the GraphPad Prism software.
2.5. Whole-genome high-resolution SNP array analysis
Affymetrix Genome-Wide Human SNP Array 6.0 was used to per-
form copy number variation analysis. The copy number variation data
of 2 patients (614, 617) were obtained from previous results with the
244 K array comparative genomic hybridization (CGH) platform
(Agilent, Santa Clara, CA). We used Affymetrix Genotyping Console
(GTC) V.4.0 and ChAS V.2.0 software to call CNVs, with all the parameter
thresholds set to default values. All annotated CNV genomic regions
were based on the hg19 (NCBI) human genome assembly. Common
variants were evaluated using the Database of Genomic Variants
(DGV) and were excluded from further analysis. Quantitative real-
time PCR was used for validation of CNVs. The ALB and TBP genes
were used as controls as previously described [13,14]. Copy number
gain or loss was determined by the comparative CTmethod. The relative
copy number values for each CNV between 0.8 and 1.2 were considered
to be normal while values≥1.3 and≤0.7 were considered as evidences
of duplication and deletion, respectively.
3. Results
3.1. Candidate gene sequencing analysis
We pooled 10 cases of barcoded sample libraries on one 316™ chip
for sequencing using the Ion PGMTM. We obtained a total alignment of
bases from 416Mb to 478Mb, with an average mean depth of coverage
of 375–421 Mb. We identiﬁed 156 variants from 27 probands (Supple-
mentary Table 1) and an average of 5.78 variants per proband. These
included 126 known single-nucleotide polymorphisms (SNPs), 11
VUSs, and 19 variants were called on homopolymer sites. Variant calls
from 5 noncoding homopolymer sites were ﬁltered out to avoid
homopolymer-associated base-calling errors. Of the 11 VUSs, 9 were
in coding regions (2were synonymous variants), and 2were in intronic
regions. Sanger sequencing conﬁrmed 5 of the 7 missense variants inTable 2
Summary of variants of unknown signiﬁcance in 27 patients with EA/TEF.
Patient ID r Chromosome
position
Gene CDS Chr Reference
nucleotide
Coverage Hom
613 42187860 GLI3 2 7 T 300 Het
328 61713068 CHD7 4 8 C 61 Het
399 61654400 CHD7 1 8 T 629 Het
611 61713055 CHD7 4 8 C 47 Het
612 16082736 MYCN 1 2 G 100 Het
29 123247625 FGFR2 12 10 T 1014 Het
618 61769072 CHD7 33 8 C 221 Het
208 42065790 GLI3 – 7 G 245 Het
619 61734504 CHD7 – 8 G 189 Hetthe coding regions (Table 2). Of the 5 conﬁrmed variants, the variant
of GLI3 (NM_000168.5, c.332 T N C, p.M111T) was predicted to be dam-
aging in silico by both SIFT and PolyPhen2, and the variant in CHD7
(NM_017780.3, c.2360C N T, p.787S N F) was predicted to be damaging
in silico by PolyPhen2 but tolerated by SIFT. The p.M111T variant of
GLI3 is novel and de novo (Fig. 1A and D). Unfortunately, the parents
were not available to test the CHD7 p.787S N F variant.
The phenotypes of the patients with the GLI3 (p.M111T) and CHD7
(p.S787F) variants were esophageal atresia with hemivertebrae and
isolated esophageal atresia, respectively.
3.2. In vitro binding assay and co-immunoprecipitation
GLI3 is a Ski-interacting protein. The N-terminal region of GLI3
(amino acids 1–397) contains the repressor domain responsible for
interacting with Ski [15,16]. To investigate whether the p.M111T muta-
tion of GLI3 affects the interaction of GLI3 with SKI family proteins, we
examined the interaction between wild-type and p.M111T-mutant
GLI3 with endogenous SKIL, a critical SKI family protein, using co-
immunoprecipitation assay.
As shown in Fig. 1E, we found that the interaction between GLI3
with SKIL was signiﬁcantly compromised in the GLI3 p.M111T mutant
(Fig. 1E). These data suggested that the p.M111T mutation affects the
physiological function of GLI3 by disrupting its interaction with SKI
family proteins.
3.3. Copy number variation analysis
We identiﬁed a total of 969 CNVs in 27 probands. Among these
CNVs, 266 were mapped in the intronic regions and 693 CNVs were re-
ported in DGV that were excluded for further analysis. Only nine CNVs
from 8 probands were rare and mapped in the gene rich regions. Four
of them, ranging in size from 175.2 Kb to 382.2 Kb at 3p14.1, 4q21.22,
10q24.2 and 17q24.3, were validated by qPCR (Table 3, Fig. 2). The
CNV in proband 386 was de novo, but the parents of the other three pa-
tients were not available for testing. Clinical signiﬁcance was evaluated
based on the literature review and genome annotation of gene content
and functions. There was no evidence immediately supporting the
clinical signiﬁcance of these CNVs. Case W43 is a male patient with
esophageal atresia IIIb and ventricular septal defect. A duplication was
found at 3p14.1 with an estimated size of 382 kb, encompassing the
SLC25A26 and LRIG1 genes. The 3p14 region is frequently detected in
various types of human cancers [17]. The LRIG1 gene has been proposed
to interact with and counteract the effects of growth factor receptors
such as EGFR [18], thereby functioning as a tumor suppressor
[19]. Case 329 is a male patient with esophageal atresia IIIb and
hemivertebrae. A duplication was found at 4q21.23 with an estimated
size of 365 kb, encompassing the HNRNPD, HNRPDL, ENOPH1 and
TMEM150C genes. Deletion of this region induces 4q21 deletion syn-
drome, which is characterized by growth restriction and mental retar-
dation [20]. Case 386 is a female patient with isolated esophageal
atresia III. De novo microduplication was found at 10q24.2 with an/Het Mutation call Amino acid
change
Interpretation SIFT PolyPhen2
c.332 T N C 111 M N T VUS 0.001 0.99
c.2360C N T 787S N F VUS 0.224 0.964
c.409 T N G 137S N A VUS 0.19 0.002
c.2347C N T 783P N S VUS 0.053 0.069
c.550G N T 184A N S VUS 1 0.301
c.1599A N G 533C N C VUS – –
c.7233C N T 2411A N A VUS – –
IVS1242 + 8C N T Intron VUS – –
IVS2835 + 18G N C Intron VUS – –
Fig. 1. Identiﬁcation of theGLI3mutation and functional analysis of GLI3 protein. A: The p.M111Tmutation ofGLI3 identiﬁed byNextGENeTM software. The FASTAﬁlewas derived from the
Ion Torrent Server. Nucleotides highlighted in blue indicate the mutation. B: Chromosomal location of GLI3. C: Schematic view of the GLI3 structure. The red vertical line indicates the
p.M111T mutation. In the N terminal region, each black vertical line indicates a reported mutation from The Human Gene Mutation Database (HGMD, public database). ZFD is the Zinc
Finger Domain, PC is the Protein Cleavage site, and TA1 and TA2 are the two transactivator domains. Greig cephalopolysyndactyly syndrome (GCPS) is caused by mutations upstream
orwithin the zinc ﬁnger domain. Pallister–Hall syndrome (PHS) is caused bymutations affecting themiddle third of the protein. D: Sanger sequencing results conﬁrmed the de novo, het-
erozygous p.M111Tmutation; E: The in vitro translatedGLI3 (WT) or p.M111Tmutant and those that bound to SKILwere analyzed byWestern blotting and are indicated by a histogram in
the right panel. **: p b 0.005.
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andHPSE2 genes. The 10q24 duplication has previously been implicated
in split hand footmalformation, but no patient with EA/TEF has been re-
ported [21]. Case 614 is a male patient with esophageal atresia, ventric-
ular septal defect, coagulation dysfunction, hypothyroidism and
hypokalemia. A duplication was found at 17q24.3 with an estimated
size of 249 kb, encompassing the SLC39A11 gene. Neither deletion/
duplication of this region nor abnormality of the SLC39A11 gene has
been related to EA/TEF. Although chromosome anomalies have been re-
ported in approximately 6%–10% of individuals with EA/TEF, none of the
detected CNVs are proposed to contribute towards gastrointestinal
malformations. Copy number variants may not be the common cause
in the investigated EA/TEF cohorts.
4. Discussion
The GLI3 gene encodes a zinc ﬁnger protein belonging to the GLI
family and functions as a transcription factor that regulates the Sonic
hedgehog (SHH) signal transduction pathway [22]. The SHH-GLI path-
way is one of many signaling pathways controlling the development
of the primitive gut. The importance of SHH signaling in esophageal
development was conﬁrmed with Glimutant mice, in which a 50% re-
duction of Gli3 expression in Gli2–/– mice resulted in EA/TEF and severe
lung deﬁciencies [23]. These results suggest that mutations in the GLI3
gene may be involved in human foregut malformations. However, toTable 3
Characteristics of detected rare copy number variants.
Patient ID Cytoband Chromosome start (hg19) Chromosome end (hg19)
W43 3p14.1 66415348 66797568
329 4q21.22 83163011 83528606
386 10q24.2 100092010 100267283
614 17q24.3 70521861 70770996our knowledge, no GLI3 gene structure aberrations or sequence varia-
tions were detected in patients with isolated or syndromic EA/TEF.
Mutations in GLI3 are associated with two dominant human syn-
dromes: Greig cephalopolysyndactyly syndrome (GCPS) and Pallister–
Hall syndrome (PHS) [9]. The genotype–phenotype correlation of the
GLI3 gene has been demonstrated based on mutation location and clas-
siﬁcation. Mutations upstream of the zinc ﬁnger domain (the repressor
domain) or within the zinc ﬁnger domain of the GLI3 gene are associat-
ed with GCPS; mutations downstream of the zinc ﬁnger region includ-
ing the protease cleavage site correlate with PHS (Fig. 1B and C). A
similar phenomenon was observed in the mouse homologue [24]. The
protein truncation mutations in GLI3 are associated with PHS, whereas
haploinsufﬁciency of GLI3 induces GCPS [25,26]. These results strongly
suggest that these two allelic disorders have distinct modes of patho-
genesis. In this study,we present a female patient (No. 613)with esoph-
ageal atresia IIIa and hemivertebrae, carrying a c.332 T N C transition
caused by a heterozygous mutation, p.M111T, in exon 3 of the GLI3
gene. This mutation is de novo and is located in the N-terminal region.
The N-terminal region of GLI3 contains the repressor domain [27].
Thus far, all identiﬁed mutations mapped within the repressor domain
were nonsense mutations (T122X, L162X, and E236X) or frame-shift
mutations (M309fs, L346fs and E411fs), which should remove most
regions of the 1580 amino acid wild-type protein and induce GCPS by
haploinsufﬁciency [24,26,28,29]. However, we present a missense mu-
tation, p.M111T, in this region. Using co-immunoprecipitation assays,Size (kb) Event Inheritance Genes
382.22 Gain NA SLC25A26, LRIG1
365.595 Gain NA HNRNPD, HNRPDL, ENOPH1, TMEM150C
175.273 Gain de novo PYROXD2,MIR1287, HPS1, HPSE2
249.135 Gain NA SLC39A11
Fig. 2. Copy number variation analysis and qPCR validation.Four copy number variation proﬁles detected by SNP array and CGH array in 4 patients and validated by real-time PCR. X-axis:
genomicmapping; Y-axis: log2 copy-number values. A: CaseW43presented a duplication on 3p14.1with an estimated size of 382 kb; B: Case 329presented a duplication on4q21.23with
an estimated size of 365 kb; C: Case 386 presented a duplication on 10q24.2 with an estimated size of 175 kb; D: Case 614 presented a duplication on 17q24.3 with an estimated size of
249 kb.
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signiﬁcantly compromised by the p.M111T mutation of GLI3. This is a
milder functional defect than haploinsufﬁciency; therefore, it may
contribute to a less severe and atypical phenotype of Pallister–Hall
syndrome.
PHS is a disorder that affects the development of many parts of the
body that is characterized by hypothalamic hamartoma, central and
postaxial polydactyly, imperforate anus, renal anomalies, and foregut-
related anomalies. Although biﬁd epiglottis is a common ﬁnding in
PHS, posterior laryngeal and tracheoesophageal cleft are uncommon
in this disorder [30]. Likewise, hemivertebrae is not a major criterion
for diagnosis of PHS and is present only in a few cases [31,32]. We con-
clude that the missense mutation in the repressor domain of the GLI3
gene is associated with esophageal atresia and hemivertebrae, which
are partially consistent with PHS.
Zentner et al. [33] reviewed 254 individuals and found that approx-
imately 19% of CHD7 mutation-positive CHARGE syndrome patients
also present with EA/TEF. Case 328, a female patient with esophageal
atresia III and patent foramen ovale, carried the transition c.2360C N T,
which causes the heterozygous variant p.787S N F in exon 4 of CHD7
(NM_017780.3). The p.787S N F residue is proximal to the chromatin or-
ganizationmodiﬁer (chromo) domain,which is a conserved region. Un-
fortunately, the parents were not available to test for the CHD7 p.787S N
F variant in this study. Although it remains to be conﬁrmed, we predict-
ed that this variant may contribute to EA/TEF.
In this study, we analyzed genomic copy number variants and
screened six esophageal atresia-related genes for protein-coding vari-
ants. However, several limitations in our study may still be worth
discussing and may be improved in the future. For example, several
other genes, such as EFTUD2 and HOXD13, which are known to cause
EA, will be included in further studies. Secondly, the role of GLI3 in the
pathogenesis of EA/TEF should be further investigated by extending
the same analysis to a larger sample size and by conducting the study
in vivo.
In summary, we detected a de novo heterozygous mutation in the
GLI3 gene in a patient with esophageal atresia and hemivertebrae. This
mutation affected the protein–protein interaction between GLI3 and
SKIL, which suggests the functional relevance of the mutation. To our
knowledge, this is the ﬁrst report that links a GLI3 gene mutation to
esophageal atresia in humans, which has been suggested in studies
with animal models. Our ﬁndings suggest that esophageal atresia
should be added to the clinical spectrum of phenotypes caused by
mutations in GLI3.
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